Introduction {#sec1-1}
============

Hemostasis is a body reaction that occurs sequentially to stop the bleeding. When blood vessels are damaged or broken, then the hemostasis process must occur quickly in areas that have been damaged and carefully controlled to be effective. Three major mechanisms that occur to reduce blood loss are vascular spasm, platelet plug formation, and coagulation (blood clotting) \[[@ref1]\].

The process of hemostasis can occur without any additional injury to the blood vessels of patients with a history of heart disease and abnormalities in blood vessels \[[@ref1]\]. In other words, thrombosis is the formation of a pathological hemostatic plugin blood vessels that do not bleed \[[@ref2]\]. For example, in patients with transient ischemic attacks (TIAs), cerebrovascular disease (stroke), myocardial infarction or peripheral artery blockage are classified as cardiovascular disease (CVD) \[[@ref3]\].

Cardiovascular disease (CVD) is the leading cause of disability and premature death worldwide. The underlying pathology of CVD is atherosclerosis \[[@ref4]\]. According to the World Health Organization (WHO) in 2012 \[[@ref5]\]. Deaths caused by noncommunicable diseases (NCDs) account for 38 million of the 56 million global deaths, which is about 68%. The main cause of NCD death in 2012 is cardiovascular disease (CVD) that is as many as 17.5 million deaths, or 46% of all deaths due to NCD.

In the Asia / Pacific region, the main cause of death is CVD, which is estimated at 9.3 million deaths and accounts for about a third of all deaths in 2012 \[[@ref3]\].

According to WHO-Noncommunicable Diseases (NCD), Country Profiles in 2014 \[[@ref6]\]. Cardiovascular disease (CVD) has been the leading cause of death in Indonesia, which is about 37% of all deaths (1,551,000) in the country.

Administration of antiplatelet drugs such as aspirin can reduce mortality caused by CVD. This antiplatelet therapy is said to be effective in treating severe vascular disease with both short-term and long-term administration \[[@ref7]\]. Aspirin (Acetylsalicylic acid-ASA) works by inhibiting the synthesis of thromboxane A2 (TXA2) in platelets and prostacyclin (PGI2) in blood vessels by irreversibly inhibiting cyclo-oxygenase enzymes \[[@ref8]\]. However, the dose of aspirin used as an antiplatelet drug in clinical trials is not equivalent \[[@ref9]\]. Excessive administration of single-dose aspirin, as well as long-term, can cause the risk of poisoning \[[@ref10]\]. The severity of complications that occur with aspirin depends on the dose and duration of treatment. Complications can include bleeding and perforation of the gastrointestinal system \[[@ref11]\]. It turns out that any pharmacological therapy has adverse side effects either directly or indirectly. Then safe, natural ingredients are needed as alternative pharmacological therapies or as supplements \[[@ref12]\].

Honey is a sweet and thick liquid with a unique flavour generated by honeybees \[[@ref13]\]. Honey is very efficacious in medical therapy because of the existence of various phenolic components that have many biological activities, including antioxidants and anti-inflammatory \[[@ref14]\]. Research conducted by Ahmed et al., in 2011 \[[@ref15]\], proved to have the effect of anti-platelet honey. Honey contains flavonoids, including hesperetin that serves as anti platelet aggregation \[[@ref16]\].

With the effect of antiplatelet on honey, the researchers are interested in researching the comparison of the effectiveness of aspirin with honey as antiplatelet based on measurement of bleeding time on the tail of mice. This research is expected to be useful in preventing CVD both in primary and secondary.

Material and Methods {#sec1-2}
====================

Types of Research {#sec2-1}
-----------------

This research is a true experimental design because it performs randomisation (simple random sampling), control, and treatment. The study design is the posttest-only control group design.

P = Population (Mice);

R = Randomization;

K1 = Ex. Plasebo Control (-) without treatment;

K2 = Ex. Plasebo Control (+) with aspirin administration without treatment;

K3 = Ex. Treatment by giving oral Honey for 12 days.

Simple random sampling {#sec2-2}
----------------------

Number labels are created on each animal that meets the inclusion criteria.Then select as many as 32 mice from them to be sampled and divided into 4 groups at random.

Provision of intervention in experimental animals (mice) was made single-blind.

Time and Place of Study {#sec2-3}
-----------------------

This research has been conducted in Pharmacology Laboratory of Department of Pharmacology and Therapeutics Faculty of Medicine, University of Sumatera Utara. This research has been conducted from September to December 2015. Research has been conducted after obtaining approval from Ethical Clearance from the Ethics Commission of the Faculty of Medicine, University of North Sumatra.

Population and Sample Research {#sec2-4}
------------------------------

In this study have been used male mice (Mus musculus), Double Ditsch Webster strains age: ± 3 months (adult), weight 20-30 grams, healthy, has never been used for other studies. Mice obtained from Laboratorium FMIPA Biology University of North Sumatra Medan. The number of group animals is determined by the formula, according to Federer (1963), as follows:

(t-1) (n-1) ≥ 15

Explanation:

n = sample size

t = number of groups of experimental animals

Then the required sample size is:

(t-1) (n-1) ≥ 15

(4-1) (n-1) ≥ 15

(n-1) ≥ 5

n ≥ 6

It takes a sample of six animals for each group based on Federer's formula. Added with an estimated drop out of 10%, then the minimum sample size required for each group are seven animals.

Based on the minimum number of samples allowed statistically and not violating the 3 R (Reduction, Replacement, Refinement) principles in the experimental animal studies, the sample size is taken to eight for each group. So, the total number of experimental animals used is 32 mice.

Criteria for Inclusion, Exclusion and Drop Out {#sec2-5}
----------------------------------------------

*Inclusion Criteria:* 1. Mice (Mus musculus) strain Double Ditsch Webster, male, age: 2-3 months, weight: 20-30 grams and 2. Mice healthy, active moves and come from the same group

*Exclusion Criteria:* Previous mice have received drug intervention.

*Drop Out Criteria:* Mice die within the study period.

Material {#sec2-6}
--------

In this study, the materials used are 1. High Desert® 75 mg Honey and 2. Aspirin 80 mg.

Preparing and Maintaining Animals Try {#sec2-7}
-------------------------------------

Before the study, the adaptation of animals at the site with a light 12-hour cycle of dark schedule, a standard diet that is eating and drinking ad libitum. The food consumed comes from Charoen Pokhpand. Try animals kept at 25 ± 10°C, 60% relative humidity. Mice were preserved during the study period; weight was weighed before and after the trial.

Procedures {#sec2-8}
----------

Male mice (Mus musculus), DDW strain, healthy, weight: 20-30 grams, divided into 4 groups: 1. Normal mice as control (-); 2. Mice with aspirin but not given intervention (positive control); 3. Mice with oral honey for 12 days; and 4. Admission was performed on the mice from the first day of the study, for 12 days at doses according to the Conversion Dosage [Table 1](#T1){ref-type="table"}.

###### 

Table Dosing Calculation Calculations (Laurence & Bacharach, 1964) orally

                      Mice 20 gram   Mouse 200 gr   Guinea Pig 400 gr   Rabbit 1,5 kg   Cat 2 kg   Monkey 4 kg   Dog 12 kg   Human 70 kg
  ------------------- -------------- -------------- ------------------- --------------- ---------- ------------- ----------- -------------
  Mice 20 gr          1.0            7.0            12.25               27.8            29.7       64.1          124.2       387.9
  Mouse 200 gr        0.14           1.0            1.74                3.9             4.2        9.2           17.8        56.0
  Guinea Pig 400 gr   0.08           0.57           1.0                 2.25            2.4        5.2           10.2        31.5
  Rabbit 1,5 kg       0.04           0.25           0.44                1.0             1.08       2.4           4.5         14.2
  Cat 2 kg            0.03           0.23           0.41                0.92            1.0        2.2           4.1         13.0
  Monkey 4 kg         0.016          0.11           0.19                0.42            0.45       1.0           1.9         6.1
  Dog 12 kg           0.008          0.06           0.1                 0.22            0.24       0.52          1.0         3.1
  Human 70 kg         0.0026         0.018          0.031               0.07            0.076      0.16          0.32        1.0

Conversion Dosage Calculation: 1. Aspirin: 80 mg x 0.0026 x 1000: 20 = 10.40 mg / kg BW and 2. Honey: 75 mg x 0.0026 x 1000: 20 = 9.75 mg / kg BW;

After 12 days of intervention, all mice have been tested for measuring bleeding time by using Duke-Tail bleeding method as follows: 1. The area under investigation (tail of mice) has been cleaned with cotton alcohol; 2. First, the tail of the mice is cut (made wound) at 1 mm diameter using a scalpel and let the blood out freely, when the blood starts stopwatch is run; and 3. Exhausted blood is sucked with filter paper every 30 seconds until the blood stops flowing (do not let filter paper touch the wound), the stopwatch is stopped when the blood cannot be sucked again using filter paper, and the time is recorded.

Data Collection {#sec2-9}
---------------

Data collected in this study were primary data obtained from the measurement of bleeding time in mice tail after 12 days of intervention.

Data Analysis {#sec2-10}
-------------

The data obtained have been analysed using a computer program. The data have been tested for normality by using the Shapiro-Wilk test because of the small number of samples. Followed by a homogeneity test using the Levene test. The Kruskal-Wallis non-parametric statistical test is performed because the data distribution is normal but the data variant is not the same (not homogeneous), followed by post hoc analysis using the Mann Whitney test. A difference is significant when p \< 0.05.

Results {#sec1-3}
=======

Description of Research Location {#sec2-11}
--------------------------------

This research was conducted in Pharmacology Laboratory of Department of Pharmacology and Therapeutics Faculty of Medicine, University of Sumatera Utara. The location is located on Jalan Dr T. Mansur, No. 5, Medan, North Sumatera.

Description of Research Sample {#sec2-12}
------------------------------

In this study used as many as 32 male mice (Mus musculus), Double Ditsch Webster strains age: ± 3 months (adult), healthy, weight 20-30 grams as a sample, which is divided into 4 groups each amounting to 8 mice, the control group (placebo), the aspirin group and the honey group.

Results of Data Analysis {#sec2-13}
------------------------

The antiplatelet effect in mice counted from the time of bleeding was analysed using a computer program. From the research obtained data as follows:

Data in [Table 2](#T2){ref-type="table"} and [Figure 1](#F1){ref-type="fig"} showed the meantime of bleeding at the highest mouse tail was in group of mice with aspirin (mean = 369.38 sec) then followed by group of mice with honey (mean = 304.63 seconds), and the lowest was the control group (placebo) with a mean value of 102.88 seconds.

###### 

Bleeding Time Taken for Mice (sec)

  Group               N   Mean     SD       Median   Minimum   Maximum
  ------------------- --- -------- -------- -------- --------- ---------
  Control (Placebo)   8   102.88   15.93    101.50   74.00     125.00
  Aspirin             8   369.38   120.97   402.00   201.00    507.00
  Honey               8   304.63   141.29   380.50   248.00    536.00
                                            326.50   129.00    462.00

![Mean Time Bleeding of Mice (sec)](OAMJMS-7-3416-g001){#F1}

Test Data Normality {#sec2-14}
-------------------

Data on bleeding time in each group were tested for normality by using the Shapiro-Wilk test. The results show that the data is normally distributed (p \> 0.05), presented in [Table 3](#T3){ref-type="table"}.

###### 

Normality Test Result of Bleeding Time

  Group               N   p       Explanation
  ------------------- --- ------- -------------
  Control (Placebo)   8   0.847   Normal
  Aspirin             8   0.188   Normal
  Honey               8   0.133   Normal

Data Homogeneity Test {#sec2-15}
---------------------

Data on bleeding time on mouse tail were tested homogeneity by Levene's test. The results show a non-homogeneous data variant (p \< 0.05), presented in [Table 4](#T4){ref-type="table"}.

###### 

Homogeneous Test of Time Bleeding between Groups

  Levene Statistic   df1   df2   Sig.     Explanation
  ------------------ ----- ----- -------- -----------------
  9,760              3     28    0.0001   Not Homogeneous

Comparability Test {#sec2-16}
------------------

The comparability test aims to compare the meantime of bleeding in the placebo, aspirin and honey groups. Based on the result of the normality and homogeneity test, the data in this research are normally distributed but do not have the same variant (not homogeneous). The comparative analysis used is a non-parametric test that is Kruskal-Wallis. Non-parametric Kruskal-Wallis statistical tests showed significant differences in at least two treatment groups (p = 0.0001), thus followed by a post hoc analysis with Mann Whitney test.

Advanced Test (Post Hoc Test) {#sec2-17}
-----------------------------

The follow-up test aims to see which groups have significant differences. In this study, the follow-up test used was the Mann Whitney test. The results of the test analysis are presented in [Table 5](#T5){ref-type="table"}.

###### 

Data Analysis with Mann Whitney Test

  Group               Control (Placebo)   Aspirin   Honey
  ------------------- ------------------- --------- ---------
  Control (Placebo)   \-                  0.001\*   0.001\*
  Aspirin             0.001\*             \-        0.172
  Honey               0.001\*             0.172     \-

Data in [Table 5](#T5){ref-type="table"} showed that there was a significant difference between aspirin and honey group to the control group (placebo), i.e., p = 0.001. There was no significant difference between aspirin group to honey (p = 0.172).

Discussion {#sec1-4}
==========

This study is a true experimental design study to prove the effect of antiplatelet on honey and to know the comparison of effectiveness between aspirin with honey as antiplatelet based on the measurement of duration of bleeding in mice tail. The time of bleeding is the time to start bleeding on the tail of the mice that are cut until the blood stops. The presence of antiplatelet effect indicated by honey is characterised by the longer time of bleeding after the treatment of wound on the tail of mice.

The average bleeding time in the treatment group given honey was longer than the control group (placebo) and almost close to the average time of positive control group bleeding (aspirin). This is so because of flavonoids. One of the contents of honey has an antiplatelet activity that can be associated with the increased production of prostacyclin by endothelial cells. The prostacyclin inhibits the aggregation process through cAMP synthesis which will inhibit the expression of GPIIb / IIIa platelet receptors \[[@ref17]\]. Inhibition of the aggregation process leads to an average time of bleeding in the tail of the mouse with prolonged honey and propolis. From the statistical test, there were significant differences in bleeding time in the control group (placebo) against the treatment group given honey. In the treatment group treated with honey showed no significant difference to the positive control group (aspirin). This proves that honey has antiplatelet effects in mice as do aspirin.

The mechanism of inhibition of platelet aggregation by honey depends on several factors. A study has shown that exposure to hydrogen peroxide (one of honey content) can lead to platelet activity inhibition of platelet aggregation \[[@ref18]\]. Also, honey may affect platelet function by inhibiting LDL oxidation that indirectly inhibits platelet aggregation \[[@ref19]\]. This is because research has shown that activated platelets after aggregation will produce some cytokines that activate phagocytes resulting in increased production of oxygen free radicals that will eventually lead to the oxidation of LDL \[[@ref18]\]. The active component of propolis CAPE has been shown to have an antiplatelet effect based on the following mechanism by increasing the formation of cGMP which will activate the cyclic phosphorylation of GMP-dependent VASP Ser157 and then inhibit the activity of PKC (protein kinase C). In the end, there is inhibition of phosphorylation of P47 and triggers the inhibition of platelet aggregation \[[@ref20]\].

From the results of this study, it turns out the average time of bleeding in the tail of mice with the provision of honey longer or closer to the positive control group (aspirin). It can be considered as an alternative antiplatelet therapy or as a supplement in the prevention of heart disease and blood vessels. Therefore, further research needs to be done on humans for more effective results as well as doing this research using a large sample.

In conclusion, based on data analysis obtained in this study, the conclusions are: 1) this study proves that honey can provide an antiplatelet effect in mice with the occurrence of lengthening of bleeding time on the tail and 2) the mean bleeding time in mice tail (304.63 sec) was close to the meantime of bleeding with aspirin (369.38 sec) so that honey could be considered as a supplement in treating heart disease and blood vessels.
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